Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“The USPSTF lung cancer screening recommendations in 2013 and 2021 have harmed at-risk populations ever since they imposed complex eligibility criteria intended to optimize the benefits of early detection with annual LDCT scans. These recommendations, now codified as billing requirements, have created barriers that impeded uptake for over a decade through complicated pack-year and quit-time thresholds, which are burdensome to ascertain and continue to exclude many high-risk individuals.
As the USPSTF prepares its 2026 update, it must acknowledge the limitations of these requirements and their unintended consequences, and commit to simpler, more inclusive criteria—because missed screenings lead to missed cancers, and missed cancers cost lives.”
More posts featuring Drew Moghanaki.